Maryanne Senna, MD, assistant professor of dermatology at Harvard Medical School, discusses the results of the case and the impact JAK inhibitors have had on the treatment of alopecia areata ...

Currently approved therapies for alopecia areata are all JAK inhibitors and carry boxed warning labels, King noted. Bempikibart simultaneously inhibits the IL-7 receptor, which "rebalances" T ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Two JAK inhibitors were recently approved by the United States Food and Drug Administration for severe alopecia areata. Baricitinib, or Olumiant (Eli Lilly/Incyte), was approved for severe ...

USA: In a significant advancement for the treatment of severe alopecia areata (AA), long-term data from two phase III ...

1 "With these data, baricitinib is the most well-studied JAK inhibitor in severe alopecia areata, a chronic immune system disorder that can have an especially devastating social and emotional ...

Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg Patients treated with baricitinib 4 mg saw significant ...